takeoff.watch

A therapy is approved for slowing human ageing

Will the FDA or the European Medicines Agency approve a drug or therapy with a labelled indication of slowing human ageing or extending healthy lifespan?

Chance by Q4 2031

2%

Cumulative probability

0%25%50%75%100%
  • Latest forecast

Forecast history

Forecast made on 17 Oct 2026

Latest of 5 forecasts · Methodology v2.1

Model reasoning

Forecast made 17 Oct 2026 · Methodology v2.1

I put the chance that the FDA or the EU approves a drug labelled to slow ageing or extend healthy lifespan by end-2031 at about 2%. No such approval has ever happened, regulators say there is no accepted way to measure it, and the trials that could provide evidence are unfunded or will not report until 2028–2031. The development that would most change this is a large trial in older adults showing a drug preserves overall health, followed quickly by a sponsor's filing.

Where things stand (17 Oct 2026)

Neither the FDA nor the EMA has ever approved a human drug with an indication for ageing or healthspan, and no such application is known to be under review. The record from regulators is clear:

Pipeline: what could produce a qualifying label by end-2031

Reference class and base rate

  • No ageing indication has ever been approved. Disease-prevention or general labels with no specific disease behind them are rare and slow.
  • Metformin never gained a diabetes-prevention label despite the 2002 Diabetes Prevention Program trial result.
  • Sarcopenia got a diagnostic code in 2016 and still has no approved drug.
  • A five-year window is far shorter than the trial, filing and review chain needed. My per-year hazard starts near zero and rises slowly as PROSPR or PREVENTABLE data could arrive in 2029–2031.

Paths to YES (rough contributions to the ~2.2% total)

Path Contribution
A positive VITAL-H/PROSPR result leading to a fast filing and a label like "slow ageing-associated decline in intrinsic capacity" ~0.5%
A positive PREVENTABLE result turned into a disability-free-survival label ~0.4%
A dedicated Lilly/Novo healthspan programme approved by 2031 ~0.3%
A politically driven FDA action (this administration has used 1–2 month priority-voucher reviews and FDA-initiated label changes) ~0.4%
Other sponsors, the EMA, or a borderline label that resolvers count ~0.5%

Reading adopted

The words in Indications and Usage (or EU section 4.1) must explicitly refer to ageing or healthspan. Function- or disease-specific wording does not count. A broad label such as "slow ageing-associated decline in intrinsic capacity" or "prolong disability-free survival" would probably count.

Strongest case against my estimate

There is unprecedented alignment: an FDA research agenda on aging, ARPA-H endpoints work, Big Pharma interest, and an administration willing to make fast, unconventional approvals. A five-year window gives room for a surprise. This is why I did not go below 1%. But the evidence the FDA says it needs (multi-year hard-outcome trials) cannot plausibly finish, be filed and be reviewed before 2032.

Computation. I set quarterly hazards of 0.03% (Q4 2026), 0.05% (2027), 0.08% (2028), 0.10% (2029), 0.14% (2030) and 0.18% (2031), and took cumulative = 1 − ∏(1 − h) in Python. That gives 0.23% by end-2027, 0.95% by end-2029 and 2.2% by end-2031.

Resolution criteria

Opened 16 Sep 2026Not yet resolved

Question. By the last day of each quarter, has the FDA or the European Medicines Agency approved a drug or therapy with a labelled indication of slowing human ageing or extending healthy lifespan?

Definitions.

  • Approval: FDA marketing approval of a human drug or biological therapy, including an original or supplemental NDA or BLA; or European Commission centralised marketing authorisation following EMA assessment, including an indication extension. FDA accelerated approval and EU conditional authorisation or authorisation under exceptional circumstances count. An EMA/CHMP recommendation without the Commission's authorisation does not count.
  • Drug or therapy: a medicinal treatment, including small molecules, biologics, cell therapies and gene therapies, whether new or repurposed.
  • Labelled indication: an authorised use in the FDA prescribing information's Indications and Usage section or the EU Summary of Product Characteristics' section 4.1, Therapeutic indications, or their official successor sections. Claims elsewhere about mechanisms, trial endpoints or potential benefits do not constitute an indication.
  • Slowing human ageing: an indication explicitly to slow, delay, prevent or reverse human biological ageing itself, rather than solely to treat or prevent named diseases or local manifestations of ageing.
  • Extending healthy lifespan: an indication explicitly to extend human healthspan or the duration of life in good health, including an explicit equivalent such as prolonging life free of age-related morbidity or disability generally. Merely improving survival, reducing mortality, improving quality of life, or preventing a specified disease does not qualify.
  • A qualifying indication may be restricted to an age group or other defined patient population; it need not apply to everyone. No minimum effect size and no AI contribution are required.

Resolves YES if an official resolving source publishes confirmation of a granted approval and its authorised indication satisfies either the slowing-ageing or healthy-lifespan definition. Both the granted authorisation and qualifying indication must be publicly documented by the horizon.

Resolves NO / Exclusions.

  • No qualifying public documentation by the horizon.
  • Trial authorisations or IND clearance, expanded access, emergency-use authorisations, orphan or expedited-development designations, regulatory acceptance of an endpoint, or applications and favourable opinions awaiting approval.
  • Veterinary products, supplements, cosmetics, off-label prescribing, clinic marketing claims, and device clearances.
  • Approval solely for a particular disease, including progeria or other progeroid syndromes, Alzheimer's disease, glaucoma or frailty, without an independently qualifying ageing or healthspan indication. In particular, Zokinvy's existing disease-treatment and disease-specific mortality indications do not qualify.
  • Biological-age biomarker changes or cellular rejuvenation mentioned only as mechanisms or study results; inferred longevity benefits from reductions in disease risk; or disease-free survival limited to a specific disease.

Resolving source. FDA-approved prescribing information and approval records in Drugs@FDA, or FDA-published biological-product approval records; EMA European Public Assessment Reports and their authorised product-information annexes, together with European Commission centralised authorisation decisions where needed. These official regulatory records are the exclusive resolving sources, rather than the broader Public confirmation convention A2 sources. An assessment report describing a proposed indication is insufficient without final authorisation. Apply the Resolution window and Resolution date convention A3: only qualifying publications on or after 2026-09-16 count, and resolution occurs on publication of the last document needed to establish approval and the indication, not a retrospectively reported approval date. Once YES, always YES, even if approval is later withdrawn.

Download all forecasts (JSON)